These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33283988)

  • 1. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults.
    Dusetzina SB; Muluneh B; Keating NL; Huskamp HA
    N Engl J Med; 2020 Dec; 383(24):2299-2301. PubMed ID: 33283988
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
    Egilman AC; Wallach JD; Ross JS; Dhruva SS
    JAMA Intern Med; 2018 Apr; 178(4):567-569. PubMed ID: 29340562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
    Dusetzina SB; Huskamp HA; Keating NL
    JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole AL; Dusetzina SB
    Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.
    Chen CT; Kesselheim AS
    J Oncol Pract; 2017 Jun; 13(6):352-355. PubMed ID: 28445102
    [No Abstract]   [Full Text] [Related]  

  • 8. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 10. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Medicare Part D Savings on Ophthalmic Generic Drugs.
    Collet DA; Urban MB; Amin A
    JAMA Ophthalmol; 2024 Jul; 142(7):678-680. PubMed ID: 38814578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health spending projections through 2016: modest changes obscure part D's impact.
    Poisal JA; Truffer C; Smith S; Sisko A; Cowan C; Keehan S; Dickensheets B
    Health Aff (Millwood); 2007; 26(2):w242-53. PubMed ID: 17314105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
    Egilman AC; Kesselheim AS; Sarpatwari A; Rome BN
    Ann Intern Med; 2024 Jun; 177(6):833-835. PubMed ID: 38684101
    [No Abstract]   [Full Text] [Related]  

  • 15. $4 generics: How low, how broad, and why patient engagement is priceless.
    Rucker NL
    J Am Pharm Assoc (2003); 2010; 50(6):761-3. PubMed ID: 21071325
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bexarotene: A Case Study of Medicare Part D's Specialty Drug Shortcomings.
    Puri P; Rajkumar SV; Shah ND; Pittelkow MR; Mangold AR
    Mayo Clin Proc; 2021 Oct; 96(10):2519-2522. PubMed ID: 34531065
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipitor goes generic: business as usual or more big business?
    Gill L; Santa J; Peter DL; Keehn J
    Ann Intern Med; 2012 Jun; 156(12):892-3, W313. PubMed ID: 22711082
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicare and prescription drugs.
    Iglehart JK
    N Engl J Med; 2001 Mar; 344(13):1010-5. PubMed ID: 11274630
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.